Dutch DPI developer PureIMS has announced the appointment of Bram van Dijck as its new Chief Executive Officer, succeeding Reinier Schwietert, who is stepping down as CEO but will remain with the company. Van Dijck was most recently Global Head Portfolio Management at the Grünenthal Group and has worked in executive positions at numerous pharmaceutical companies, including Cipla, Hospira, Teva Pharmaceuticals, Organon and Abbott Laboratories.
PureIMS is developing several DPI products based on its Cyclops disposable dry powder inhaler platform, including levodopa for Parkinson’s, colistin and tobramycin for CF, amikacin for tuberculosis, and epinephrine for anaphylaxis. The company said, “Mr. van Dijck’s appointment to the leadership team coincides with PureIMS transitioning from an academic spin-off to a mature pharmaceutical company focusing on the final development of its clinical-stage lead programs Levodopa Cyclops and Epinephrine Cyclops.”
Van Dijck said, I am thrilled to join PureIMS at a stage where my specific expertise will be complementary to the knowledge of the existing team. I look forward to working with the highly motivated PureIMS crew and to leading the company through its next phase towards commercialization.”
Carduso Capital partner Robert Polano commented, “On behalf of the PureIMS investors I am pleased to welcome Bram to the PureIMS leadership. We have great confidence in his capacities that will be critically important at a time where the company aims to raise new funding and, either itself or through a partnership, bring its lead programs to the stage of marketing authorization. Bram’s broad expertise with medical devices and pharmaceuticals, combined with his senior leadership experience, makes him the ideal candidate to lead the company to successfully realizing these new ambitions.”
Read the PureIMS press release.
